KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Common Equity (2018 - 2025)

BioNTech SE's Common Equity history spans 8 years, with the latest figure at $22.4 billion for Q4 2025.

  • On a quarterly basis, Common Equity rose 7.88% to $22.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $22.4 billion, a 7.88% increase, with the full-year FY2025 number at $21.7 billion, up 4.71% from a year prior.
  • Common Equity hit $22.4 billion in Q4 2025 for BioNTech SE, up from $21.6 billion in the prior quarter.
  • Over the last five years, Common Equity for BNTX hit a ceiling of $22.4 billion in Q4 2025 and a floor of $3.0 billion in Q1 2021.
  • Historically, Common Equity has averaged $18.2 billion across 5 years, with a median of $20.6 billion in 2024.
  • Biggest five-year swings in Common Equity: skyrocketed 895.88% in 2021 and later dropped 8.22% in 2025.
  • Tracing BNTX's Common Equity over 5 years: stood at $13.6 billion in 2021, then surged by 50.39% to $20.5 billion in 2022, then rose by 6.46% to $21.8 billion in 2023, then decreased by 4.78% to $20.7 billion in 2024, then grew by 7.88% to $22.4 billion in 2025.
  • Business Quant data shows Common Equity for BNTX at $22.4 billion in Q4 2025, $21.6 billion in Q3 2025, and $20.9 billion in Q2 2025.